1 / 29

Anticoagulant Safety Remains a Problem

Anticoagulant Safety Remains a Problem. Emergency Hospitalizations for Adverse Drug Events. Comparative Pharmacology. Inducers and Inhibitors of Cytochrome P450 3A4 and P-gp. Novel Anticoagulants for Stroke Prevention in AF. Trials With NOACs vs Warfarin in AF.

vincent-petty
Télécharger la présentation

Anticoagulant Safety Remains a Problem

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Anticoagulant Safety Remains a Problem

  2. Emergency Hospitalizations for Adverse Drug Events

  3. Comparative Pharmacology

  4. Inducers and Inhibitors of Cytochrome P450 3A4 and P-gp

  5. Novel Anticoagulants for Stroke Prevention in AF

  6. Trials With NOACs vs Warfarin in AF

  7. All NOACs and Stroke or SE Event

  8. ENGAGE AF-TIMI 48: Primary End Point Stroke/Systemic Embolic Event (2.8-y median follow-up)

  9. ENGAGE AF-TIMI 48 Bleeding

  10. Who Should Remain on Warfarin?

  11. EINSTEIN DVT/PEStudy Designs

  12. Switching From Warfarin to NOACs

  13. Adverse Events

  14. SummaryBenefits of NOACs

  15. Abbreviations

  16. Abbreviations (cont)

  17. References

  18. References (cont)

  19. References (cont)

  20. References (cont)

  21. References (cont)

More Related